Original Research Article

Comparison of intensity modulated proton therapy beam configurations for treating thoracic esophageal cancer

Sornjarod Oonsiri, Sarin Kitpanit, Danita Kannarunimit, Chakkapong Chakkabat, Chawalit Lertbutsayanukul, Anussara Prayongrat

Division of Radiation Oncology, Department of Radiology, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Bangkok, Thailand

A R T I C L E   I N F O

Keywords:
Proton therapy
Esophageal cancer
Beam configuration

A B S T R A C T

Background and purpose: Specific proton-beam configurations are needed to spare organs at risk (OARs), including lungs, heart, and spinal cord, when treating esophageal squamous cell carcinoma (ESCC) in the thoracic region. This study aimed to propose new intensity-modulated proton therapy (IMPT) beam configurations and to demonstrate the benefit of IMPT compared with intensity-modulated x-ray therapy (IMXT) for treating ESCC.

Material and methods: IMPT plans with three different beam angle configurations were generated on CT datasets of 25 ESCC patients that were treated with IMXT. The IMPT beam designs were two commonly-used beam configurations (anteroposterior and posterior oblique) and a recently proposed beam configuration (anterosuperior with posteroinferior). The target doses were 50–54 Gy(RBE) and 60–64 Gy(RBE) to the low-risk and high-risk target volumes, respectively. Robust optimization was applied for the IMPT plans. The differences in the dose-volume parameters between the IMXT and IMPT plans were compared.

Results: With target coverage comparable to standard IMXT, IMPT had significantly lower mean doses to the OARs. IMPT with an anteroposterior opposing beam generated the lowest lung dose (mean = 7.1 Gy(RBE), V20 = 14.1%) and the anterosuperior with posteroinferior beam resulted in the lowest heart dose (mean = 12.8 Gy(RBE), V30 = 15.7%) and liver dose (mean = 3.9 Gy(RBE), V30 = 5.9%). For the subgroup of patients with an inferior tumor location (PTVs overlapping a part of the contoured heart), the novel beam demonstrated the optimal OARs sparing.

Conclusion: Compared with IMXT, the IMPT plans significantly reduced the radiation dose to the surrounding organs when treating ESCC. IMPT beam configuration selection depends on the tumor location relative to the heart.

1. Introduction

Esophageal carcinoma is the sixth leading cause of cancer death (544,000 deaths) and the seventh most common cancer worldwide (604,000 new cases) [1]. Radiotherapy (RT) is one of the mainstays of the neoadjuvant treatment of resectable cases [2,3] and the definitive treatment for unresectable or inoperable cases [4]. However, local failure within the radiation treatment volume remains a significant problem and triggers a dose-escalation strategy to enhance local control [5]. High-dose RT improves the local tumor response in esophageal cancer patients and potentially improves overall survival; however, this can result in treatment-related toxicity, despite modern techniques with intensity-modulated x-ray therapy (IMXT) [6–9].

Several dosimetric and clinical studies demonstrated that proton beam therapy (PBT) generated lower doses to the surrounding organs-at-risk (OARs) and the reduced toxicity risk, with comparable disease
margin along the esophagus, and GTV-N. A low-risk CTV (CTV-LR) included the GTV-P with a 0.5-cm radial and a 2-cm craniocaudal margin along the whole circumferential wall of the involved esophagus (GTV-P), and the gross target volume (GTV) consisted of a gross primary tumor with tumor length was 7.5 cm (range, 2.4–77 years old), and most were male (92%). The patients received concurrent chemotherapy for neoadjuvant (20%) and definitive setting (80%). Nineteen patients (76%) had upper or mid thoracic esophageal cancer and the supraclavicular region was treated in 16 patients (64%). The median tumor length was 7.5 cm (range, 2.4–14.0 cm).

2. Material and methods

We retrospectively reviewed the medical records of 25 patients with squamous cell carcinoma of the thoracic esophagus that were treated with IMXT in our institution between 2011 and 2019. The study was approved by the Institutional Review Board (no. 038/62).

The patients’ median age was 62 years-old (range 44–77 years-old), and most were male (92%). The patients received concurrent chemotherapy for neoadjuvant (20%) and definite setting (80%). Nineteen patients (76%) had upper or mid thoracic esophageal cancer and the supraclavicular region was treated in 16 patients (64%). The median tumor length was 7.5 cm (range, 2.4–14.0 cm).

2.1. Treatment planning

The computed tomography (CT) simulation images and structures from the IMXT treatment plan were used to generate dummy IMPT plans with three different beam configurations as described below. The target delineation and dose prescription were previously described [8]. Briefly, the gross target volume (GTV) consisted of a gross primary tumor with the whole circumferential wall of the involved esophagus (GTV-P), and pathologic nodes (GTV-N). A high-risk clinical target volume (CTV-HR) included the GTV-P with a 0.5-cm radial and a 2-cm craniocaudal margin along the esophagus, and GTV-N. A low-risk CTV (CTV-LR) encompassed GTV-P with a 0.5-cm radial and a 4-cm craniocaudal margin, GTV-N, and elective nodal region. A 1-cm isotropic margin was added to the CTVs to create planning target volumes (PTVs). The median PTV-LR and PTV-HR volumes were 514.9 cm$^3$ (interquartile range (IQR), 414.4–663.5) and 340.6 cm$^3$ (IQR, 243.4–432.2), respectively. The median prescription doses were 50 Gy for PTV-LR and 60 Gy for PTV-HR.

The prescription doses were 50–54 Gy relative biological effectiveness (RBE) followed by a cone-down boost to 60–64 Gy(RBE), at 2 Gy (RBE) per fraction, for the low-risk and high-risk PTV (PTV-LR and PTV-HR), respectively. The supraclavicular region was electively treated when a tumor involved the upper thoracic esophagus or upper mediastinal lymph nodes metastasis. The lungs, heart, liver, and spinal cord were contoured for all patients; however, the kidneys were delineated for those with PTVs beyond the EGJ. The heart delineation started at the caudal edge of the left pulmonary artery, following the pericardium until it blended with the diaphragm.

2.2. Beam arrangement

For the IMXT plan, 6 MV photon beams were used. The typical seven beam angles of the IMXT plan were separated into five beams for coplanar (240°, 330°, 45°, 135°, and 60°) and two beams for non-coplanar anterior fields (10° and 350° with 270° couch rotation). However, the beam angles were adjusted for each patient depending on the tumor location.

For the IMPT plan, the beam output was modulated using an RBE of 1.1. Three IMPT plans were generated using different beam angle configurations i.e., IMPT-A: anterior with posterior oblique beams (0°, 220°, and 140°); IMPT-B: anteroposterior opposing beams (0° and 180°); and IMPT-C: Superior anterior and anterior oblique beam (0° and 330°) and Superior posterior and posterior oblique beams (180° and 120°) (Fig. 1). In the IMPT-C plan, the superior and inferior beam paths were divided by the upper border of the heart. The aim of the superior beams was to treat the supraclavicular lymph node region, whereas the inferior beams avoided the heart. The superior and inferior beams were planned with a 2-cm overlapping field with a single isocenter optimization technique to avoid the uncertainties at the junction. Robust optimization (3.5% calibration curve error and 5 mm isocenter shift) was used to account for uncertainties and the interplay effect. Multifield optimization with a nonlinear universal proton optimizer was used in the IMPT technique. The criteria for dose optimization were 95% of the PTV volumes receiving the prescribed dose and maximum dose receiving lower than 107%. To evaluate the plan’s robustness, we simulated 14 error scenarios to account for possible setup and range uncertainties (3.5% for proton range uncertainties with 5 or 0 mm for setup uncertainties). In this study, the robustness evaluation criteria was that the CTV received >95% and 90% of the prescribed dose for CTV-HR and CTV-LR, respectively, in the worst-case scenario [27]. The doses in all plans were kept as low as possible to spare the lung, heart, and spinal cord.

The dose distribution of the four plans, one IMXT and three IMPT plans, based on tumor location, are depicted in Fig. 1. The treatment plans were calculated using the Eclipse$^{TM}$ treatment planning system (version 15.0, Varian Medical System, Palo Alto, CA).

2.3. Dose-volume analysis

The dose-volume data for the tumor and normal organs were collected from each treatment plan. The target coverage was represented by the dose covering at least 100% (DT$_{100%}$) of the CTVs and D$_{95\%}$ of the PTVs. For the OARs, the mean dose and volume of the structures receiving at least $\times$ Gy (V$_{\times}$) of the lungs, heart, liver, and kidneys were collected. The dose to 1 cm$^3$ (D$_{1\text{ cm}^3}$) of the spinal cord was calculated. To demonstrate the effects of each plan on the heart dose, sub-group analysis was performed for tumors in the superior location (PTVs
above the contoured heart) and the inferior location (PTVs overlapping a part of the contoured heart).

2.4. Normal tissue complication probability

To estimate the clinical significance of IMPT, the normal tissue complication probability (NTCP) was calculated and compared with IMXT for the heart and lung toxicity for each patient. A review of the literature revealed that there were only two NTCP models for predicting heart and lung toxicity in esophageal cancer patients [28,29]. For postoperative lung and heart complications, the clinical and dosimetric data from 601 patients were analyzed using multivariable logistic regression analysis to define the predictive factors. The significant predictors for lung toxicity were mean lung dose (MLD), age, body mass index (BMI), and histology (squamous cell carcinoma or adenocarcinoma) with an area under the receiver operating characteristics (AUC) of 0.79. For postoperative cardiac toxicity, age was the only predictor. A published NTCP model for pericardial effusion was derived from 297 esophageal cancer patients that were treated with definitive chemoradiation of \( \geq 50 \) Gy and followed for \( \geq 6 \) months. Mean heart dose (MHD) was a significant predictor for any grade and symptomatic (grade \( \geq 3 \)) pericardial effusion with an AUC of 0.73–0.82 [29]. The NTCP model parameters are presented in Supplement Table 1S.

2.5. Statistical analysis

The Shapiro Wilk test was used to determine the normal distribution of the data. Dose-volume parameters of the target volumes and OARs, as well as the NTCP values were compared using the paired t-test for normally distributed data; and the Wilcoxon signed-rank test was used for non-normally distributed data. A two-sided p-value threshold of less than 0.05 was used for statistical significance. The statistical analyses were performed using STATA version 15.1 (StataCorp LLC, Texas, USA).

3. Results

With similar target coverage, all IMPT plan techniques resulted in a significantly reduced dose to the OARs compared with IMXT. When the dose-volume parameters were compared between the IMPT plans, the IMPT-B plan achieved the lowest lung dose (MLD = 7.1 Gy(RBE)) and the IMPT-C plan resulted in the lowest heart dose (MHD = 12.8 Gy(RBE)), liver dose (mean liver dose = 3.9 Gy(RBE)), and spinal cord dose (\( D_{1cm3} = 36.8 \) Gy(RBE)). In eight patients with distal thoracic esophageal tumors, the left kidney dose was significantly lower in the IMPT plans (mean kidney dose = 8.6 Gy in IMXT vs. 3.1–3.3 Gy(RBE) in IMPT), whereas the right kidney dose was very low in all plans because the distal location and gastrohepatic lymph node deviated to the left side of the abdomen. The dose-volume parameters in the IMXT and three IMPT plans are presented in Table 1.

For the superior tumor location (above the contoured heart), the IMPT-B plan had better lung-sparing (MLD = 6.0 Gy(RBE)) compared with the other plans (IMXT = 12.5 Gy(RBE), IMPT-A = 7.2 Gy(RBE), and IMPT-C = 6.5 Gy(RBE)). For the inferior location, the IMPT-C plan generated the lowest heart dose parameters (MHD = 13.6 Gy(RBE) vs. IMXT = 32.9 Gy(RBE), IMPT-A = 16.0 Gy(RBE), and IMPT-B = 17.5 Gy(RBE)) with a slightly higher lung dose than the IMPT-B plan (MLD = 8.7 Gy(RBE) in IMPT-C vs. 7.4 Gy(RBE) in IMPT-B). The dose-volume data between each treatment plan on the lung and heart dose are shown in Table 2.

The IMPT plans resulted in a significantly lower risk of lung and heart toxicity compared with IMXT treatment based on the NTCP model. The risk for postoperative pulmonary complication and any grade pericardial effusion was reduced by more than 10% whereas the risk for symptomatic (grade \( \geq 3 \)) pericardial effusion was slightly reduced. The NTCP values and NTCP differences (\( \Delta \)NTCP) for the IMXT and three IMPT plans for heart and lung are as summarized in Table 3 and illustrated in Supplement Figs. 2S and 3S.

When the patients were stratified based on tumor location, the IMPT plans reduced the risk of postoperative pulmonary complication by half in both subgroups. Although the IMPT-C plan slightly reduced the cardiac risk for superior tumors, it demonstrated remarkable improvement for inferior tumors. The \( \geq 10\% \) risk reduction of any grade pericardial effusion was seen in 100% of the patients in the inferior tumor location group (Supplement Table 2S and 3S).

4. Discussion

The results of the present study revealed the dosimetric and potential benefits of IMPT in reducing the risk of lung and heart toxicity in esophageal cancer patients. The improved dose distribution and lower NTCP values indicate that IMPT is a promising modality for preserving normal tissue function while delivering high-quality radiation therapy to the target volume.
Abbreviations: IMXT = intensity-modulated radiation therapy; IMPT = intensity-modulated proton therapy; CTV = clinical target volume; PTV = planning target volume; LR = low-risk; HR = high-risk; RBE = relative biological effectiveness; D_{x}(V) = dose that x% volume received; V_{x}(RBE) = volume receiving x Gy(RBE).

Clinical benefit of IMPT for treating thoracic esophageal cancer using high-dose (≥60 Gy) radiation compared with IMXT. Among the three different beam configurations, the IMPT-B plan generated the lowest lung dose and the IMPT-C plan resulted in the optimal OARs sparing with the lowest heart dose.

The proton therapy beam configurations recommended by several studies included anteroposterior opposing beams, anterior or posterior with posterior oblique beams, or posterior with left lateral beams. However, most studies evaluated patients with cancer of the distal esophagus or EGI and prescribed a standard radiation dose (50.4 Gy or less) [13,17,24,25]. Compared with Western countries, in the Asian population many esophageal cancer tumors are not considered resectable and receive a high OARs dose due to the relatively larger tumor size, upper-mid thoracic location, and supraclavicular region irradiation. A meta-analysis found that a radiation dose ≥60 Gy improved treatment outcomes in esophageal carcinoma patients [35]. Therefore,

Table 1
Dose-volume parameter comparison between the IMXT and IMPT plans.

|                | IMXT | IMPT-A | IMPT-B | IMPT-C |
|----------------|------|--------|--------|--------|
| CTV-LR         | D_{20}(Gy) (RBE) | 54.0 | 54.9 | 53.9 | 54.4 |
| CTV-HR         | D_{20}(Gy) (RBE) | 62.5 | 63.4 | 63.2 | 63.3 |
| PTV-LR         | D_{20}(Gy) (RBE) | 54.4 | 55.2 | 54.4 | 54.9 |
| PTV-HR         | D_{20}(Gy) (RBE)| 62.1 | 63.6* | 63.6* | 63.5* |

|                | Mean (Gy) (RBE) | V_{20}(%) | V_{30}(%) | V_{40}(%) | V_{50}(%) | V_{60}(%) | V_{70}(%) |
|----------------|----------------|----------|----------|----------|----------|----------|----------|
| Liver          | Mean (Gy) (RBE)| 10.4 | 5.4* | 4.6* | 3.9 |
| Heart          | Mean (Gy) (RBE)| 27.1 | 13.2* | 14.5* | 12.8* |
| Spinal cord    | Mean (Gy) (RBE)| 42.0 | 39.7 | 38.0* | 36.8 |

|                | Mean (Gy) (RBE) | V_{20}(%) | V_{30}(%) | V_{40}(%) | V_{50}(%) | V_{60}(%) | V_{70}(%) |
|----------------|----------------|----------|----------|----------|----------|----------|----------|
| Right kidney (N = 8) | Mean (Gy) (RBE)| 2.0 | 0.9* | 0.7 | 0.1* |
| Left kidney (N = 8)  | Mean (Gy) (RBE)| 8.6 | 3.3* | 3.1 | 3.3* |

|                | Mean (Gy) (RBE) | V_{20}(%) | V_{30}(%) | V_{40}(%) | V_{50}(%) | V_{60}(%) | V_{70}(%) |
|----------------|----------------|----------|----------|----------|----------|----------|----------|
| Superior location (N = 5) | IMXT | IMPT-A | IMPT-B | IMPT-C |
| Heart          | Mean (Gy) (RBE)| 3.9 | 2.3* | 2.4* | 9.7 |
| Lung           | Mean (Gy) (RBE)| 12.5 | 7.2* | 6.0* | 6.5* |

|                | Mean (Gy) (RBE) | V_{20}(%) | V_{30}(%) | V_{40}(%) | V_{50}(%) | V_{60}(%) | V_{70}(%) |
|----------------|----------------|----------|----------|----------|----------|----------|----------|
| Inferior location (N = 20) | IMXT | IMPT-A | IMPT-B | IMPT-C |
| Heart          | Mean (Gy) (RBE)| 9.8 | 7.5 | 8.0 | 7.3 |
| Lung           | Mean (Gy) (RBE)| 51.2 | 27.3* | 16.9 | 23.1* | 73.3 | 42.2* | 22.9 | 30.4* |

*Significance level, p-value < 0.05 (as compared with IMXT).

Dose-volume parameters are presented as mean value and the paired t-test was used to compare the IMXT and IMPT results.

Abbreviations: NTCP = normal tissue complication probability; ΔNTCP = NTCP difference; IMXT = intensity-modulated radiation therapy; IMPT = intensity-modulated proton therapy; IQR = interquartile range.

Table 2
Comparison of the lung and heart doses between the IMXT and IMPT plans according to tumor location.

|                | Superior location (N = 5) | Inferior location (N = 20) |
|----------------|---------------------------|---------------------------|
| Heart          | IMXT | IMPT-A | IMPT-B | IMPT-C | IMXT | IMPT-A | IMPT-B | IMPT-C |
| Mean (Gy) (RBE)| 3.9 | 2.3* | 2.4* | 9.7 | 32.9 | 16.0* | 17.5* | 13.6* |
| V_{20}(%)      | 10.8 | 7.5 | 8.0 | 7.3 | 86.6 | 42.4* | 46.2* | 33.1* |
| V_{30}(%)      | 5.1 | 4.3 | 4.7 | 4.1 | 74.8 | 27.4* | 31.5* | 24.5* |
| V_{40}(%)      | 2.1 | 2.3 | 2.6 | 2.3 | 54.6 | 20.0* | 22.7* | 19.1* |
| V_{50}(%)      | 1.0 | 1.1 | 1.2 | 1.1 | 34.7 | 15.3* | 17.1* | 14.8* |
| V_{60}(%)      | 0.3 | 0.4 | 0.4 | 0.4 | 20.4 | 11.6* | 12.5* | 11.3* |
| V_{70}(%)      | 0.1 | 0.1 | 0.1 | 0.1 | 20.4 | 11.6* | 12.5* | 11.3* |
| V_{80}(%)      | 0.1 | 0.1 | 0.1 | 0.1 | 20.4 | 11.6* | 12.5* | 11.3* |

*Significance level, p-value < 0.05 (as compared with IMXT).

Dose-volume parameters are presented as mean value and the paired t-test was used to compare the IMXT and IMPT results.

Abbreviations: IMXT = intensity-modulated radiation therapy; IMPT = intensity-modulated proton therapy.
The anterior with posterior oblique beams were optimal for sparing the patients based on tumor location and found that PSPT lowered the mean heart dose in mid and distal esophageal lesions from 24.5 Gy and 19.7 Gy using the IMXT plan to 5.1 GyRBE and 12.8 GyRBE using the PSPT plan [18]. Compared with similar tumor locations in our study, the mean heart dose in the IMPT-C plan was 13.6 GyRBE, which was slightly higher than in Wang et al., despite the PTV dose escalation in our study (60–64 Gy).

For more modern PBT techniques, an early IMPT study performed in 10 patients at the MD Anderson Cancer Center escalated the radiation dose to the tumor (50.4 GyRBE to the PTV and simultaneously integrated the GTV boost to 65.8 GyRBE) [17]. Three beam configurations were used. The anteroposterior opposing beams resulted in the lowest lung dose, the posterior oblique beams had the best heart sparing, and the anterior with posterior oblique beams were optimal for sparing the heart and lung. The authors concluded that selecting a unique IMPT plan for each patient should be based on the patient’s anatomy and preexisting pulmonary or cardiac disease. However, the patients in their study had EGJ tumors. In contrast, our patients had tumors in the upper and mid thoracic location that had a risk for increased mean heart dose, compared with EGJ tumors [12]. Another high-dose PBT study reported a lower lung dose, but a higher heart dose, compared with our study [10]. However, because the data of the PBT technique or beam arrangement and the use of an in-house treatment planning system were not available, it was difficult to directly compare their results with ours. Several dosimetric studies of proton treatment for esophageal carcinoma are presented in Supplement Table 4.

The NTCP model is a valuable tool to translate the dosimetric advantage of IMPT into a clinical benefit. The NTCP model-based approach has been used as a strategy to select patients who will potentially benefit from PBT [32–34]. Our results confirmed the clinical benefit of IMPT because there was a significant reduction in NTCP for the heart and lungs, which was consistent with previous studies [11,25]. Unlike other prior studies, the strength of this study is the use of NTCP models that were derived from esophageal cancer patients [28,29]. Applying a common threshold of ΔNTCP > 10 percentage points to select PBT [32,35], at least two-thirds of the patients would have benefited from IMPT based on NTCP reduction of the lung or heart toxicity. The risk of pericardial effusion was reduced for all patients, and especially for the inferior tumor location, regardless of IMPT beam configuration (Supplement Table 35).

The limitations of this study were the small number of patients and the clinical outcome of the proposed IMPT beam configurations could not be determined. Furthermore, the effects of the proton therapy uncertainties, including range and setup uncertainty in a highly heterogeneous area of the chest were not evaluated. However, accurate radiation doses were safely delivered to the patients with robust optimization and proper motion management. The potential benefits of high-dose IMPT for esophageal cancer will be investigated in a prospective randomized trial at our institution (Thai Clinical Trials Registry: TCCTR 20200310006).

In conclusion, IMPT provided good target coverage, better sparing of the heart, and less NTCP compared with IMXT when high-dose radiation was given. Selecting anteroposterior opposing (IMPT-B) or superior anterior with anterior oblique beams and inferior posterior with posterior oblique beams (IMPT-C) to treat thoracic esophageal cancer depends on tumor location.

Funding
This Research was funded by the Thailand Science research and Innovation Fund Chulalongkorn University CU.FRB65_he(a) (30) _037_30_18.

Declaration of Competing Interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgement
English editing service, Research Affairs, Faculty of Medicine, Chulalongkorn University.

Appendix A. Supplementary data
Supplementary data to this article can be found online at https://doi.org/10.1016/j.pj.2022.04.005.

References
[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209-49. doi:10.3322/ caac.21660.
[2] Shapiro J, van Lanschot JJB, Hulshof M, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 2015;16:1090–8. https://doi.org/10.1016/S1470-2045(15)00046-6.
[3] Eyck BM, van Lanschot JJB, Hulshof M, van der Wilk BJ, Shapiro J, van Hagen P, et al. Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: The randomized controlled CROSS trial. J Clin Oncol 2021;39:1995-2004. https://doi.org/10.1200/JCO.20.03614.
[4] Stahl M, Budach W. Definitive chemoradiotherapy. J Thorac Dis 2017;9:S792-s. doi: 10.1002/cncr.26586.
[5] Welsh J, Settle SH, Amini A, Xiao L, Suzuki A, Hayashi Y, et al. Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer 2012;118:2632–40. https://doi.org/10.1002/cncr.26586.
[6] Chen CY, Li CC, Chien CR. Does higher radiation dose lead to better outcome for non-operated localized esophageal squamous cell carcinoma patients who received concurrent chemoradiotherapy? a population based propensity-score matched analysis. Radiother Oncol 2016;120:136-9. doi:10.1016/j.radonc.2016.04.042.
[7] Hulshof MCCM, Geijten B, Rozema T, Oppedijk V, Buijsen J, Neelis KJ, et al. A randomized controlled phase III multicenter study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer: ARTDECO study. J Clin Oncol 2021;39:2816-24. doi:10.1200/JCO.20.03697.
[8] Lerbutsayanukul C, Tharavej C, Klaikeaw N, Prayongrat A, Lowanitchai C, Suriunpong V. High dose radiation with chemotherapy followed by salvage esophagectomy among patients with locally advanced esophageal squamous cell
carcinoma. Thorac Cancer 2017;8:219–28. https://doi.org/10.1111/1759-
7714.12427.

[9] Sun X, Wang J, Wang Y, Kang J, Jiang W, Men Y, et al. High vs. low radiation dose of concurrent chemoradiotherapy for esophageal carcinoma with modern radiotherapy techniques: a meta-analysis. Front Oncol 2020;10:1222. doi: 10.3389/fonc.2020.01222.

[10] Hirano Y, Onozawa M, Hojo H, Motegi A, Zenda S, Hotta K, et al. Dosimetric comparison between proton beam therapy and photon radiation therapy for locally advanced esophageal squamous cell carcinoma. Radiat Oncol 2018;13:23. doi: 10.1186/s13041-018-0966-5.

[11] Makishima H, Ishikawa H, Terunuma T, Hashimoto T, Yamanashi K, Sekiguchi T, et al. Comparison of adverse effects of proton and X-ray chemoradiotherapy for esophageal cancer using an adaptive dose-volume histogram analysis. J Radiat Res 2015;56:568–76. https://doi.org/10.1093/jrr/rru001.

[12] Shirato H, Le QT, Kobashi K, Prayongrat A, Takao S, Shimizu S, et al. Selection of radiotherapy approaches for precise and accurate cancer treatment. Present developments in reaching an international consensus for a model-based atlas. J Radiat Res 2018;59:i1–28. doi: 10.1093/jrr/rrx092.

[13] Celik E, Baus W, Baus C, Schröder W, Clivio A, Fogliata A, et al. Volumetric modulated arc therapy versus intensity-modulated proton therapy in neoadjuvant irradiation of locally advanced oesophageal cancer. Radiat Oncol 2020;15:120. doi: 10.1186/s13040-020-00570-y.

[14] Zhang X, Zhao KL, Guerrero TM, McGuire S, Vyas S, Shimizu S, et al. Four-dimensional computed tomography-based treatment planning for intensity-modulated radiation therapy and proton therapy for distal esophageal cancer. Int J Radiat Oncol Biol Phys 2008;72:278–87. https://doi.org/10.1016/j.ijrobp.2008.05.014.

[15] Feng H, Sio TT, Rule WG, Bangsou RS, Lara P, Patrick CL, et al. Beam angle comparison for distal esophageal carcinoma patients treated with intensity-modulated proton therapy. J Appl Clin Med Phys 2020;21:141–52. https://doi.org/10.1002/acm2.13049.

[16] Zhang Z, Liao Z, Jin J, Aijani J, Chang JY, Jeter M, et al. Dose–response relationship in locoregional control for patients with stage II–III esophageal cancer treated with concurrent chemotheraphy and radiotherapy. Int J Radiat Oncol Biol Phys 2005;61:566–64. https://doi.org/10.1016/j.ijrobp.2004.06.022.

[17] Yang Z, Li H, Li Y, Li Y, Chang Y, Li Q, et al. Statistical evaluation of worst-case robust optimization intensity-modulated proton therapy plans using an exhaustive sampling approach. Radiat Oncol 2019;14:129. doi: 10.1186/s13041-019-1335-8.

[18] Thomas M, Defraene G, Lambrecht M, Deng W, Moons J, Naftneux P, et al. NTCP model for postoperative complications and one-year mortality after trimodality treatment in oesophageal cancer. Radiother Oncol 2019;141:53–60. doi: 10.1016/j.ijrobp.2019.09.015.

[19] Feng H, Sio TT, Rule WG, Bangsou RS, Lara P, Patrick CL, et al. Beam angle comparison for distal esophageal carcinoma patients treated with intensity-modulated proton therapy. J Appl Clin Med Phys 2020;21:141–52. https://doi.org/10.1002/acm2.13049.

[20] Celik E, Baus W, Baus C, Schröder W, Clivio A, Fogliata A, et al. Volumetric modulated arc therapy versus intensity-modulated proton therapy in neoadjuvant irradiation of locally advanced oesophageal cancer. Radiat Oncol 2020;15:120. doi: 10.1186/s13040-020-00570-y.

[21] Shirato H, Le QT, Kobashi K, Prayongrat A, Takao S, Shimizu S, et al. Selection of radiotherapy approaches for precise and accurate cancer treatment. Present developments in reaching an international consensus for a model-based atlas. J Radiat Res 2018;59:i1–28. doi: 10.1093/jrr/rrx092.

[22] Thomas M, Defraene G, Leijen R, Lambrecht M, Ricardiu U, et al. To investigate the influence of cardiac motion on the robustness of pencil beam scanning proton plans in oesophageal cancer. Phys Imaging Radiat Oncol 2020;16:50–3. https://doi.org/10.1002/acm2.13049.

[23] Thomas M, Defraene G, Leijen R, Lambrecht M, Ricardiu U, et al. To investigate the influence of cardiac motion on the robustness of pencil beam scanning proton plans in oesophageal cancer. Phys Imaging Radiat Oncol 2020;16:50–3. https://doi.org/10.1002/acm2.13049.

[24] Thomas M, Defraene G, Lambrecht M, Deng W, Moons J, Naftneux P, et al. NTCP model for postoperative complications and one-year mortality after trimodality treatment in oesophageal cancer. Radiother Oncol 2019;141:53–60. doi: 10.1016/j.ijrobp.2019.09.015.

[25] Celik E, Baus W, Baus C, Schröder W, Clivio A, Fogliata A, et al. Volumetric modulated arc therapy versus intensity-modulated proton therapy in neoadjuvant irradiation of locally advanced oesophageal cancer. Radiat Oncol 2020;15:120. doi: 10.1186/s13040-020-00570-y.